Continuous Manufacturing as a Default Platform for Oral Solid Drug Products


19th May 2020 | 10:00 am CEST | Lawrence De Belder, Senior Principal Engineer Continuous Manufacturing at Johnson and Johnson and Bob Lenich, Director of Life Sciences Business at Emerson |BOOK FREE SEAT FOR THIS WEBINAR

The counter is at Six today: Orkambi, Symdeko, Trikafta (Vertex); Prezista (Johnson and Johnson); Verzenio (Eli Lilly); Daurismo (Pfizer) –are all approved by the FDA – Johnson and Johnson’s Tramacet for the Japanese market not included. Several large Pharma companies have chosen the path of Continuous Manufacturing, and announced they will use this platform as their default for development and consequently – commercial manufacturing of their Oral Solid dose drug product pipeline.

During this webinar, the author will explain the consequences of this decision, and different strategies to handle a pipeline that can be highly dynamic. Different techniques will be discussed that can be used to bring products with bad flow properties into a continuous process. Impact of different equipment in development, clinical and commercial environment will be detailed out, and mitigations will be proposed to overcome these differences. All will be placed in front of a background of regulatory requirements, changing market demand, and evolving strategies of equipment vendors.

Presented by Lawrence De Belder, Senior Principal Engineer Continuous Manufacturing at Johnson and Johnson

Lawrence De Belder is a Senior Principal Engineer at Johnson & Johnson Technical Operations, a group in the Janssen Supply Chain which provides support to Janssen Commercial Operations. He has 23 years of experience designing and implementing different Manufacturing Technologies of which 12 years in Pharma and 6 years in Oral Solid Dose Continuous Manufacturing.
He is the Program Manager for Continuous Manufacturing in the Janssen Supply Chain where he manages all projects and activities on continuous manufacturing for Oral Dosage Drug Product throughout the different parts of the organization.
He has published several relevant articles, represents J&J on the most important conferences, as a speaker or as organizing committee member and is leading several consortia (CM Work Group of the IQ Consortium, GEA User group, and CM Community of Practice at ISPE), where he connects the strongest experts in the industry within the landscape of Continuous Manufacturing in Solids Small Molecules.

And Bob Lenich, Director of Life Sciences Business at Emerson

Bob is a life-long learner who stays engaged in new technology and organizational trends in order to adapt them to solving operating issues across the process industries. He works with a wide variety of organizations to identify operational problems, evaluate how to make improvements, and then justify and sell the approach. Bob loves seeing the successful deployment of a solution and then sharing the benefits so that others can take advantage of the approach. Bob gets special gratification from seeing how those improvements help areas like Life Science manufacturing improve people’s lives.

Bob currently is responsible for planning Emerson’s strategy for growing our automation business in the Life Science industry globally. He then collaboratively works across the various business units in Emerson to implement the strategy and build the business.
Bob has a BS in Chemical Engineering from Rose Hulman Institute of Technology and an MBA from the University of Texas.

Sponsored by Emerson

 

Life Sciences manufacturers strive to create innovative and reliable products that help people lead healthier lives. Emerson has the automation expertise and technology to solve your greatest cGMP manufacturing challenges and create effective solutions for improving your data management, real-time product quality, reliability, and operating costs. From design to implementation and startup to on-going optimization, rely on Emerson to stay competitive in a global economy.Save

Save

Save

Save

Save


We will not sell your information to a third party. See our Privacy Policy